AzurRx BioPharma Inc (NASDAQ:AZRX) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus target price of $8.25 for the company and are anticipating that the company will post ($0.23) EPS for the current quarter, according to Zacks. Zacks has also given AzurRx BioPharma an industry rank of 179 out of 265 based on the ratings given to its competitors.
Separately, HC Wainwright set a $8.00 price objective on shares of AzurRx BioPharma and gave the stock a “buy” rating in a report on Friday.
AzurRx BioPharma (NASDAQ:AZRX) traded down $0.07 on Friday, reaching $3.34. 28,543 shares of the company traded hands, compared to its average volume of 64,151. AzurRx BioPharma has a 52 week low of $2.40 and a 52 week high of $5.25.
AzurRx BioPharma (NASDAQ:AZRX) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.13). analysts predict that AzurRx BioPharma will post -1.05 earnings per share for the current year.
WARNING: “AzurRx BioPharma Inc (AZRX) Given $8.25 Average Price Target by Brokerages” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/01/20/azurrx-biopharma-inc-azrx-given-8-25-average-price-target-by-brokerages.html.
About AzurRx BioPharma
AzurRx BioPharma, Inc is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company’s product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.